Authors: Ellen Colvin, Future Science Group
A team of scientists, funded by the Innovative Medicines Initiative (IMI), the COMBACTE-NET (Combatting Bacterial Resistance in Europe) consortium, and sponsored by AstraZeneca (Cambridge, UK), have completed a Phase II clinical trial using suvratoxumab, a novel monoclonal antibody (mAb), designed to target Staphylococcus aureus.
The SAATELLITE trial is part of the collaborative research program, New Drugs 4 Bad Bugs (ND4BB), striving to innovate alternative medicines for the impending post-antibiotic era as a result of resistance.
SAATELLITE was an important landmark in the COMBACTE-NET consortium as it is the first clinical trial executed within the ND4BB scheme and an important step in progressing towards reaching one of the major goals of the program, to aid in suvratoxumab (MEDI4893) development.
The mAb produced by AstraZeneca, targets a toxin produced by the opportunistic pathogen, Staphylococcus aureus, with hopes of preventing ventilator-associated pneumonia (VAP) in intensive care unit (ICU) patients, among other nosocomial infections. The trial saw its testing in eligible patients, deemed as such after confirmation using real-time polymerase chain reaction (PCR) assaying, to determine Staphylococcus aureus presence in the lower respiratory tract.
The collaborative work of the COMBACTE-NET consortium is the first European initiative bringing together experts in various specialisms from epidemiology to critical care, with inputs from researchers to pharmaceutical professionals, collaborating with universities and hospitals striving towards the same end goal in promoting and fast-tracking development of novel anti-infectives to combat antimicrobial resistance.